Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
ivonescimab
product6 mentionslast seen Oct 24, 2026
A novel, potential first-in-class investigational bispecific antibody combining immunotherapy via PD-1 blockade with anti-angiogenesis effects from VEGF blocking.
Relationships 23
- ivonescimabapplies tocolorectal cancer100% confidence1 source
- Akeso Inc.developsivonescimab99% confidence4 sources
- Summit Therapeutics Inc.developsivonescimab99% confidence3 sources
- ivonescimabcomposed ofPD-1 blockade99% confidence2 sources
- ivonescimabapplies tourothelial carcinoma99% confidence2 sources
- ivonescimabapplies tonon-small cell lung cancer treatment99% confidence2 sources
- ivonescimabapplies tonon-small cell lung cancer99% confidence2 sources
- ivonescimabcomposed ofVEGF blocking99% confidence2 sources
- ivonescimabapplies tocolorectal cancer99% confidence1 source
- ivonescimabapplies tobiliary tract cancer99% confidence1 source
- Summit Therapeutics Inc.developsivonescimab99% confidence1 source
- Akeso Inc.approvesivonescimab95% confidence1 source
- ivonescimabapplies toimmuno-oncology drug development93% confidence1 source
- ivonescimabdepends onPD-1 / VEGF bispecific antibody93% confidence1 source
- ivonescimabapplies tobiliary tract cancer treatment92% confidence1 source
- ivonescimabapplies tourothelial carcinoma treatment92% confidence1 source
- ivonescimabapplies tocolorectal cancer treatment92% confidence1 source
- ivonescimabapplies togastrointestinal cancer treatment92% confidence1 source
- HARMONi-2 trial overall survival analysiscitesivonescimab90% confidence1 source
- Summit Therapeutics Inc.depends onivonescimab90% confidence1 source
- ivonescimabapplies tomedical tourism85% confidence1 source
- Summit Therapeutics Inc.approvesivonescimab75% confidence1 source
- U.S. Food and Drug Administrationapprovesivonescimab75% confidence1 source
Relationship
ivonescimabapplies tourothelial carcinoma
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 15, 2026Summit Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
HARMONi-GU1, a Phase II/III study in urothelial carcinoma (bladder cancer)
- filingSEC EDGARSep 14, 2026Summit Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
HARMONi-GU1, a Phase II/III study in urothelial carcinoma (bladder cancer)